T-Cell-Based Platform for Functional Screening of T-Cell Receptors Identified in Single-Cell RNA Sequencing Data Sets of Tumor-Infiltrating T-Cells.
Anti-tumor reactivity
T-cell activation
T-cell receptor
Tumor-infiltrating lymphocytes
mRNA transfection
Journal
Bio-protocol
ISSN: 2331-8325
Titre abrégé: Bio Protoc
Pays: United States
ID NLM: 101635102
Informations de publication
Date de publication:
20 Apr 2024
20 Apr 2024
Historique:
received:
23
01
2024
revised:
14
03
2024
accepted:
14
03
2024
medline:
30
4
2024
pubmed:
30
4
2024
entrez:
30
4
2024
Statut:
epublish
Résumé
The advent of single-cell RNA sequencing (scRNAseq) has enabled in-depth gene expression analysis of several thousand cells isolated from tissues. We recently reported the application of scRNAseq toward the dissection of the tumor-infiltrating T-cell repertoire in human pancreatic cancer samples. In this study, we demonstrated that combined whole transcriptome and T-cell receptor (TCR) sequencing provides an effective way to identify tumor-reactive TCR clonotypes on the basis of gene expression signatures. An important aspect in this respect was the experimental validation of TCR-mediated anti-tumor reactivity by means of an in vitro functional assay, which is the subject of the present protocol. This assay involves the transient transfection of mRNA gene constructs encoding TCRα/β pairs into a well-defined human T-cell line, followed by co-cultivation with the tumor cells of interest and detection of T-cell activation by flow cytometry. Due to the high transfectability and the low background reactivity of the mock-transfected T-cell line to a wide variety of tumor cells, this assay offers a highly robust and versatile platform for the functional screening of large numbers of TCR clonotypes as identified in scRNAseq data sets. Whereas the assay was initially developed to test TCRs of human origin, it was more recently also applied successfully for the screening of TCRs of murine origin. Key features • Efficient functional screening of-and discrimination between-TCRs isolated from tumor-reactive vs. bystander T-cell clones. • Applicable to TCRs from CD8
Identifiants
pubmed: 38686347
doi: 10.21769/BioProtoc.4972
pii: e4972
pmc: PMC11056003
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e4972Informations de copyright
©Copyright : © 2024 The Authors; This is an open access article under the CC BY-NC license.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare no competing interests.
Références
Cancer Immunol Res. 2014 Dec;2(12):1230-44
pubmed: 25245536
PLoS One. 2020 Sep 9;15(9):e0238875
pubmed: 32903281
Nature. 2014 Nov 27;515(7528):572-6
pubmed: 25428506
Cell Chem Biol. 2023 Jul 20;30(7):739-752.e8
pubmed: 37321224
JAMA Oncol. 2017 Jun 01;3(6):774-783
pubmed: 27768182
Protein Eng. 2003 Sep;16(9):707-11
pubmed: 14560057
Blood. 2006 Dec 15;108(13):4009-17
pubmed: 16940422
Cancer Cell. 2017 Aug 14;32(2):185-203.e13
pubmed: 28810144
Nat Med. 2021 Mar;27(3):515-525
pubmed: 33479501
Nature. 2022 May;605(7910):532-538
pubmed: 35508657
Cancer Cell. 2022 Apr 11;40(4):410-423.e7
pubmed: 35413272
Cancer Gene Ther. 2021 Feb;28(1-2):5-17
pubmed: 32457487
Front Immunol. 2022 Apr 27;13:867189
pubmed: 35572552
Trends Immunol. 2016 Nov;37(11):724-737
pubmed: 27614798
Nature. 2021 Aug;596(7870):126-132
pubmed: 34290408
Cancer Res. 2007 Apr 15;67(8):3898-903
pubmed: 17440104
Cell Mol Immunol. 2022 Jan;19(1):33-45
pubmed: 34417572
J Immunother. 2003 Jul-Aug;26(4):332-42
pubmed: 12843795
Nat Cancer. 2021 May;2(5):563-574
pubmed: 34927080
Curr Opin Immunol. 2016 Aug;41:9-17
pubmed: 27155075
Sci Transl Med. 2023 Nov 15;15(722):eadh9562
pubmed: 37967201
Nat Rev Cancer. 2020 Apr;20(4):218-232
pubmed: 32024970
Clin Cancer Res. 2020 Aug 15;26(16):4289-4301
pubmed: 32303540
Nat Commun. 2020 May 1;11(1):2176
pubmed: 32358491
Nat Rev Clin Oncol. 2020 Oct;17(10):595-610
pubmed: 32572208
Science. 2022 Feb 25;375(6583):877-884
pubmed: 35113651